Skip to Content
  • 3.5
    Impact Factor
  • 7.7
    CiteScore
  • 18 days
    Submission to First Decision
  • 3 days
    Acceptance to Publication

Vaccines

Vaccines is an international, peer-reviewed, open access journal on laboratory and clinical vaccine research, utilization and immunization, published monthly online by MDPI. The Polish Society of Vaccinology (PTW) is affiliated with Vaccines and its members receive discounts on the article processing charges.

Get Alerted

Add your email address to receive forthcoming issues of this journal.

All Articles (10,582)

  • Article
  • Open Access

Background/Objectives: Under high measles vaccination coverage, breakthrough infections often present with mild, atypical features that may delay outbreak recognition. We characterized measles cluster outbreaks in a high-coverage setting, focusing on the interval between primary-case and index-case onset as a measure of delayed outbreak recognition. Methods: We investigated three measles cluster outbreaks comprising 66 laboratory-confirmed cases reported in Henan Province, China, in 2025, using field investigation and laboratory testing, and compared clinical manifestations by immunization status; because of profound age differences between immunization groups, comparisons were presented descriptively. Results: The interval from primary- to index-case onset ranged from 4 to 15 days, representing an upper-bound estimate of the recognition delay. All three primary cases had received two doses of measles-containing vaccine (MCV) and presented with low-grade fever and localized rash, whereas none of the four index cases had an MCV history and all had peak temperatures ≥39 °C. Among the 21 infected close contacts identified from 100 screened close contacts, 84.6% (11/13) of vaccinated (≥1 dose) individuals were asymptomatic or mild, versus 37.5% (3/8) of unvaccinated or status-unknown individuals. Among cases with documented immunization history, pneumonia (17.4% vs. 37.5%) and hospitalization (43.5% vs. 62.5%) were less frequent in vaccinated than in unvaccinated cases; these unadjusted differences were confounded by age and are presented descriptively. Conclusions: Breakthrough measles infections in high-coverage settings have atypical presentation and mild symptoms. Such infections may lead to unrecognized community transmission. Surveillance should incorporate active case finding for atypical presentations in high-coverage high-density settings.

Vaccines

20 November 2026

(A) Monthly distribution of the 66 laboratory-confirmed measles cases reported in Henan Province in 2025; shaded areas indicate the periods of the three cluster outbreaks investigated (Xiping, January–February; Dengfeng, May and July; Wenxian, August). (B) Interval between primary-case and index-case onset in the three cluster outbreaks.
  • Article
  • Open Access

Background/Objectives: We investigated COVID-19-related outcomes and the real-world effectiveness of COVID-19 vaccination against hospitalization and death among children, adolescents, and young people (CYP) with obesity. Methods: In this nationwide population-based retrospective cohort study, we analyzed CYP (2–25 years) with laboratory-confirmed COVID-19 recorded in the official Brazilian national surveillance databases between February 2020 and December 2025. For the analysis, the sample was divided into two cohorts according to the presence of obesity. The outcomes of interest were COVID-19-related hospitalization and death. Vaccine effectiveness (VE) against hospitalization and death was estimated using multivariable logistic regression models. The number needed to vaccinate (NNV) to prevent one outcome was estimated in a propensity score-matched cohort, with adjustments for confounders. Results: The cohort comprised 6,904,083 individuals with COVID-19, including 18,149 individuals with obesity (0.3%). After controlling for confounding factors, patients with obesity were at a higher risk of hospitalization (OR = 3.7, 95% CI, 2.6–5.3) and death (OR = 2.1, 95% CI, 1.9–2.3) compared with those without obesity. The estimated VE against death due to SARS-CoV-2 infection for fully vaccinated individuals was 54.1% (95% CI 50.9–57.2) and 71.5% (95% CI 63.0–78.1%) for the non-obesity and obesity cohorts, respectively. After matching, it was estimated that the NNV to prevent one death was 10 (95% CI, 7–14) for CYP with obesity associated with other comorbidities and 25 (95% CI, 20–45) for those without comorbidities. In contrast, the respective figures for the non-obesity cohort were 117 (95% CI, 99–142) and 2168 (95% CI, 1362–2567) for those with and without comorbidities. Conclusions: CYP with obesity had a higher risk of death than those without obesity. Vaccination was associated with lower risks of hospitalization and death among vaccinated individuals with obesity, reinforcing the importance of prioritizing this high-risk group.

Vaccines

20 November 2026

  • Conference Report
  • Open Access

At a workshop held on 26–28 April 2026, leaders of advanced vaccinology courses met to advance the goals of the International Collaboration on Advanced Vaccinology Training (ICAVT), help courses address key challenges, and promote joint activities and information-sharing. They reviewed ICAVT’s scope, objectives, roles, tools, progress since 2022, and changes in the course landscape. The meeting also aimed at strengthening networking, especially between well-established and newer member courses. Discussions focused on strengthening collaboration, improving communication with members and audiences, supporting twinning between courses, and exploring AI and new teaching approaches in vaccinology education. Participants also identified priority topics, reviewed how to measure course impact on careers and vaccination programs, considered support for new courses, and addressed governance issues. Sustainable funding remained the main and growing constraint. A major ICAVT achievement is the successful annual online Advanced Refresher Course in Vaccinology (ARVAC). The meeting called for ICAVT to evolve from a loose network into a more interactive, transparent, and member-driven collaboration with shared resources, clearer institutional value, sustainable course models, and improved internal communication. A few adjustments to existing communication channels, notably internal ones, were made. The meeting discussed the latest development of AI in vaccinology and in adult education and its potential contribution in support of vaccinology training.

Vaccines

20 November 2026

  • Perspective
  • Open Access

A Coupled Platform Under Stress: PEPFAR Funding Disruption and Pediatric Immunization in Sub-Saharan Africa

  • Nguyen Khoi Quan,
  • Ufuoma Nicole Agbaire and
  • Andrew W. Taylor-Robinson
  • + 1 author

Sub-Saharan Africa carries the world’s highest burden of “zero-dose” children (i.e., infants who have not received a first dose of diphtheria–tetanus–pertussis-containing vaccine, DTP1). Across 2019–2022, 28.7 million zero-dose children were recorded cumulatively in the WHO African Region, concentrated in deprived households. Reaching this vulnerable population relies on donor-financed primary healthcare platforms. The January 2025 pause in USAID/PEPFAR funding, and the suspensions and reductions that followed, interrupted the salaries of about 190,000 health care workers, with scaled-back outreach and supply shortages documented at country level. This disruption exposes a structural reality: disease-specific (“vertical”) and healthcare system (“horizontal”) donor funding cannot be severed independently, as both rely on the same workforce, facilities, and supply chains. Between 2004 and 2018, countries with PEPFAR Country Operational Plans showed an 8–11% increase in childhood immunizations (an association, not proof of a causal effect). No study has yet measured the pediatric coverage consequences of the 2025 disruption, and household surveys will register them only years later; the current absence of data must not be interpreted as evidence that primary healthcare platforms for the most deprived children remain intact. We distinguish documented, observed, and hypothesized links in this chain and propose early warning indicators for financing transitions.

Vaccines

20 November 2026

Featured Articles of Last Quarter

Surface expression of CD14 and HLA-DR in naïve monocytic THP-1 cells and on THP-1-derived macrophage-like cells after PMA plus IFN-γ. Overlays include the corresponding isotype-control antibody. (a) CD14 on monocytic cells; (b) CD14 on macrophage-like cells; (c) HLA-DR on monocytic cells; (d) HLA-DR on macrophage-like cells.
Mechanism of adaptive immune response to a vaccine. Illustration of immune system activation by major vaccine platforms. Arrows show cascade of immune activation and where vaccine platforms exert effects. In lymph nodes and other secondary lymphoid organs, antigens from SLPs or antigens (from loaded DCs) are ingested by immature dendritic cells and presented via MHC I and II to naive CD8 T cells, CD4 T cells, and B cells. Mature immune cells migrate to the tumor site, where CD4+ T cells and B cells secrete pro-inflammatory cytokines, while CD8+ T cells and NK cells promote tumor cell lysis.

Highly Accessed Articles

News & Conferences

Latest Issues

Open for Submission

Journal Sections

XFacebookLinkedIn
Vaccines - ISSN 2076-393X